

Intended Use

Aurora Estradiol Assay is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of Estradiol (E2) in human serum and plasma. The assay kit is intended for in vitro diagnostic use.

Summary

Estradiol (E2) is an estrogen steroid hormone and the major female sex hormone. It is also known as 17β-estradiol (to distinguish it from 17 α -estradiol) or as estra-1,3,5(10)-triene-3,17 β -diol. It has two hydroxyl groups, one at the C3 position and the other at the 17B position, as well as three double bonds in the A ring. Due to its two hydroxyl groups, estradiol is often abbreviated as E2. It is important in the development and maintenance of female reproductive tissues such as the mammary glands, uterus and vagina during puberty, adulthood and pregnancy. It also has important effects in many other tissues including bone, fat, skin, liver, and the brain. Though estradiol levels in males are much lower than in females, estradiol has important roles in males as well. The Estradiol blood test measures the amount of estradiol in the blood. Estradiol levels reflect follicular maturation, the measurement of estradiol is a valuable tool in the assessment of sexual development, amenorrhea etiology, infertility and menopause causes. High levels of estradiol in males are indicative of feminizing syndromes such as gynecomastia.

Test Principle

The Estradiol assay is a quantitative competitive immunoassay to determine the presence of E2 in human serum and plasma using CMIA technology with flexible assay protocols.

- 1. Sample, and paramagnetic anti-E2 coated microparticles are mixed, E2 present in the sample is displaced from the E2 binding protein and binds to anti-E2 coated microparticles, forming an antigen antibody complex.
- 2. After incubation, a conjugate containing acridinium-labeled E2 is added to the reaction

mixture and binds to unoccupied binding sites of the anti-E2 coated microparticles.

- 3. After further incubation and washing, Pre-Trigger and Trigger Solutions are added to the reaction mixture.
- 4. The resulting chemiluminescent reaction is measured as relative light units (RLUs). There is a relationship between the amount of E2 in the sample and the RLUs detected by the Optical system. Results are calculated automatically based on the previously established calibration curve.

Reagents

neagents	•
R1	3.0 mL
R2	3.0 mL
CAL	Contains 3 levels, 1.0 mL each level
CON	Contains 2 levels, 1.0 mL each level
R1:	Microparticles. Anti-E2 coated microparticles.
	Preservative: 0.05% ProClin 300
R2:	Conjugate. Acridinium-labeled E2.
	Preservative: 0.05% ProClin 300
CAL:	Calibrator. Solutions of different
	concentrations of E2. Preservative: 0.05%
	ProClin 300
CON:	Control. Tris buffer solution for quality control

Required Materials

of Estradiol (E2)

- Pre-Trigger Solution: Hydrogen peroxide solution.
- Trigger Solution: Sodium hydroxide solution.
- Wash Buffer: Phosphate buffered saline solution with 0.05% ProClin 300.

Safety Precautions

- Exercise the normal precautions required for handling all laboratory reagents.
- Disposal of all waste material should be in accordance with local guidelines.
- Wear gloves when handling specimens or reagents.
- Clean and disinfect all spills of specimens or reagents using a suitable disinfectant.
- Trigger solution contains sodium hydroxide (NaOH) and should be avoided contact with eyes.

Warning (Contains Proclin 300)

Hazardous Component: 0.05% Proclin 300

• Reaction mass of: 5-chloro-2-methyl-4-isothiazolin [EC no. 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC no. 200-239-6] (3:1)

Hazard Statement

- H317: May cause an allergic skin reaction.
- H319: Causes serious eye irritation.
- H410: Very toxic to aquatic life with long-lasting effects.

Precautionary Statement

- P261: Avoid breathing dust/fume/gas/mist/vapors/spray.
- · P264: Wash hands thoroughly after handling.
- P272: Contaminated work clothing should not be allowed out of the workplace.
- P280: Wear protective gloves/protective clothing/eye protection/face protection.
- P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
- P337+P313: If eye irritation persists: Get medical advice/attention.
- P333+P313: If skin irritation or rash occurs: Get medical advice/attention.
- P302+P352: IF ON SKIN: Wash with plenty of soap and water.
- P321: Seek immediate care from a doctor.
- P363: Wash contaminated clothing before reuse.
- P273: Avoid release to the environment.
- P391: Collect spillage.
- P501: Dispose of contents/container in a safe way.

Reagent Handling

- Do not use reagent kits beyond the expiration date.
- Do not pool reagents within a kit or between kits.
- Before loading the reagent kit on the system for the first time, the microparticle bottle requires mixing to resuspend microparticles that may have settled during shipment.
- Septums MUST be used to prevent reagent evaporation and contamination and to ensure

reagent integrity. Reliability of assay results cannot be guaranteed if septums are not used according to the instructions in this package insert.

- To avoid contamination, wear clean gloves when placing a septum on an uncapped reagent bottle.
- Once a septum has been placed on an open reagent bottle, do not invert the bottle as this will result in reagent leakage and may compromise assay results.

Reagent Storage

REAGENT	Storage	Maximum	
REAGENT	Temperature	Storage Time	
Unopened	2°C∼8°C Do not	12 months	
Onopened	freeze.	12 1110111113	
On board/	2°C∼8°C Do not	28 days	
Opened	freeze.	20 uays	

• Reagents may be stored on or off the Chemiluminescence immunoassay analyzer. If reagents are removed from the analyzer, store them at 2-8°C (with septums and replacement caps) in an upright position. For reagents stored off the system, it is recommended that they be stored in their original trays and boxes to ensure they remain upright. If the microparticle bottle does not remain upright (with a septum installed) while in refrigerated storage off the system, the reagent kit must be discarded.

Calibrator & Control Storage

<u> </u>					
CAL	CON	Storage	Maximum		
CAL		Temperature	Storage Time		
Unopened		2°C~8°C	12 months		
Opened		2°C∼8°C	30 days		

Applicable Analyzer

Automatic Chemiluminescence Immunoassay Analyzer (model: Aurora S-01 System).

Specimen Types

Verified specimen types to be used with this assay:

Specimen Types	Collection Tubes	
Serum	Serum separator tubes (SST)	
	Dipotassium EDTA	
Plasma	Tripotassium EDTA	
PidSilid	Sodium heparin	
	Lithium heparin powder	

Plasma separator tubes (PST)
-lithium heparin gel

- Other specimen collection tube types have not been tested with this assay.
- Liquid anticoagulants may have a dilution effect resulting in lower concentrations for individual patient specimens.
- The instrument does not provide the capability to verify specimen type. It is the responsibility of the operator to verify that the correct specimen types are used in the assay.

Specimen Conditions

Do not use specimens with the following conditions:

- · Heat-inactivated
- Pooled
- Grossly hemolyzed (> 500 mg/dl hemoglobin)
- Obvious microbial contamination
- Fungal growth
- For accurate results, serum and plasma specimens should be free of fibrin, red blood cells, and other particulate matter. Serum specimens from patients receiving anticoagulant or thrombolytic therapy may contain fibrin due to incomplete clot formation.
- To prevent cross contamination, use of disposable pipettes or pipette tips is recommended.

Preparation for Analysis

- Follow the tube manufacturer's processing instructions for collection tubes. Gravity separation is not sufficient for specimen preparation.
- Mix thawed specimens thoroughly by low speed vortexing or by inverting 10 times. Visually inspect the specimens. If layering or stratification is observed, continue mixing until specimens are visibly homogeneous.
- Avoid more than 5 freeze/thaw cycles.
- To ensure consistency in results, specimens must be transferred to a centrifuge tube and centrifuged for a minimum of 30,000 g-minutes before testing if they contain fibrin, red blood cells, or other particulate matter, they were previously frozen.
- Examples of acceptable time and force ranges that meet this criterion are listed in the table below. Centrifugation time using alternate Relative

Centrifugal Force values (RCF) can be calculated using the following formula:

Centrifugation Time (Minutes)	RCF (×g)	g × minutes
10	3,000	30,000
15	2,000	30,000
20	1,500	30,000

- Transfer clarified specimen to a sample cup or secondary tube for testing. For centrifuged specimens with a lipid layer, transfer only the clarified specimen and not the lipemic material.
- Inspect all specimens for bubbles. Remove bubbles with an applicator stick before analysis. Use a new applicator stick for each specimen to prevent cross contamination.

Specimen Storage

Specimen Tupe	Storage	Maximum	
Specimen Type	Temperature	Storage Time	
	Room	≤8 hours	
Serum/Plasma	temperature	≥ 8 Hours	
	2°C∼8°C	≤ 7 days	
	-20°C	≤ 180 days	

- Remove serum or plasma from the clot, red blood cells, or separator gel if stored longer than the maximum room temperature storage time.
- Remove serum or plasma from the clot, red blood cells, or separator gel if stored longer than the maximum 2-8°C storage time and store frozen.
- Frozen specimens must be mixed thoroughly after thawing.
- Use caution in handling patient specimens to prevent cross-contamination.
- Do not exceed the storage limitations listed above.

Assay Procedure

- Refer to the system operating instruction or the online help system for detailed information on preparing the system.
- Before loading the reagent kit on the system for the first time, the microparticle bottle requires mixing to resuspend microparticles that may have settled during shipment. After the first time the

Aurora E2 Assay CARBONTECHNOLOGIES

microparticles have been loaded, no further mixing is required.

- Invert the microparticle bottle 30 times. Visually inspect the bottle to ensure microparticles are resuspended. If microparticles are still adhered to the bottle, continue to invert the bottle until the microparticles have been completely resuspended. If the microparticles do not resuspend, DO NOT USE. Once the microparticles have been resuspended, place a septum on the bottle.
- Load the reagent kit on the Chemiluminescence immunoassay analyzer.
- Verify that all necessary reagents are present.
- Verify adequate sample volume is present prior to running the test.
- Sample volume for first test: 250 μL
- Sample volume for each additional test from same sample cup: 80 µL
- The test-specific parameters stored in barcode on the reagent pack are read in. In cases the barcode cannot be read, enter the sequence numbers
- · Order calibration, if necessary.
- Prepare Estradiol Calibrators and Controls.
- Mix calibrator(s) and controls by gentle inversion before use.
- Hold bottles vertically and dispense recommended volumes into each respective sample cup.
- Place the calibrators in the calibrator rack in the sample zone.
- · Calibration.
- Load samples. For information on loading samples, refer to the Analyzer's Operations Manual.
- Press RUN.
- The Chemiluminescence immunoassay analyzer performs all the functions automatically and calculates the results.

For optimal performance, it is important to perform routine maintenance as described in the Analyzer's Operations Manual. Perform maintenance more frequently when required by laboratory procedures.

Sample Dilution Procedures

 Samples with a E2 value exceeding 1000 pg/mL may be diluted using the Manual Dilution Procedure.

Manual Dilution Procedure

Suggested dilution: 1:10

- Add 100 μL of the sample to 900 μL of Stroke physiological saline solution or dilutions.
- The operator must enter the dilution factor in the Patient or Control order screen. The system will use this dilution factor to automatically calculate the concentration of the sample before dilution and report the result.

Calibration

- Traceability: This assay has been standardized against the ID-GC/MS.
- Every E2 assay kit has a two-dimension code label containing the predefined master curve of the particular reagent lot.
- Test Calibrators in duplicate. The calibrators should be priority loaded. A replicate of each control level must be tested to evaluate the assay calibration. Ensure that assay control values are within the ranges specified in the respective control package insert.
- Once calibration is accepted and stored, all subsequent samples may be tested without further calibration unless:
- After 28 days when using the same lot reagent.
- A reagent kit with a new lot number is used.
- Controls are out of range.
- Required by pertinent regulations.
- Assay may also need to be recalibrated after specified service procedures have been performed or maintenance to critical part or subsystems that might influence the performance of the assay. For detailed information on how to perform an assay calibration, refer to the Analyzer's Operations Manual.
- Calibration Range: 10 pg/mL~1000 pg/mL.

Aurora E2 Assay CARBONTECHNOLOGIES

Quality Control Procedures

- · Order Control, if necessary.
- The recommended control requirement for the Aurora E2 assay is that a single replicate of each control level be tested:
- Once every 24 hours each day of use
- · After performing calibration
- After instrument service procedures or maintenance that may affect assay performance have been performed.
- If the quality control procedures in your laboratory require more frequent use of controls to verify test results, follow your laboratory-specific procedures.
- Each laboratory should establish control ranges to monitor the acceptable performance of the assay. If a control is out of its specified range, the associated sample results are invalid and the samples must be retested. Recalibration may be indicated.
- These results should be applied to your laboratory's quality control practices. In addition, the laboratory must ensure that the matrix of the control material is suitable for use in the assay per the assay package insert.
- Unless specified, target values and ranges provided with the commercial control product insert are guidelines only and should not be used for quality control purposes.
- Refer to Clinical and Laboratory Standards Institute (CLSI) Document C24-A3, or other published guidelines for general quality control recommendations.

Results

Calculation

• The analyzer automatically calculates the concentration of each sample. The results are given in pg/mL.

Alternate Result Units

- The default result unit for the Aurora E2 assay is pg/mL. When the alternate result unit, pmol/L, is selected, the conversion factor used by the system is 3.67.
- Conversion Formula:

(Concentration in pg/mL) × (3.67) = Concentration in pmol/L.

Limits

- Results should be used in conjunction with other data; e.g., symptoms, results of other tests, and clinical impressions.
- If the E2 results are inconsistent with clinical evidence, additional testing is recommended.
- Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Such specimens may show either falsely elevated or depressed values when tested with assay kits that employ mouse monoclonal antibodies. Additional information may be required for diagnosis.
- Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference, and anomalous values may be observed. Additional information may be required for diagnosis.
- Rheumatoid factor (RF) in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Additional information may be required for diagnosis.
- The Estradiol assay is susceptible to interference effects from triglycerides at > 500 mg/dL.

Expected Values

- It is recommended that each laboratory establish its own reference range, which may be unique to the population it serves depending upon geographical, season, patient, dietary, or environmental factors. A study was performed based on guidance from Clinical and Laboratory Standards Institute (CLSI) C28-A3c.
- Human serum specimens from apparently healthy individuals were collected the 513 specimens, 384 were female and 129 were male, age between 21 and 90 years.

The population	n	Reference range*
Premenopausal Apparently	125	24 pg/mL~489

Aurora E2 Assay CARBONTECHNOLOGIES

healthy female		pg/mL
Postmenopausal Apparently healthy female	127	≤ 52 pg/mL
1~12 weeks pregnant apparently healthy female	132	≥ 221 pg/mL
Apparently healthy male	129	≤ 44 pg/mL

*According	to	the	95th	percentile	or	2.5th~97.5th
percentile o	r 5	th pe	ercent	tile.		

*Representative data; results in individual laboratories and in different geographical areas may vary from these data.

Specific Performance Characteristics

- Data in this section were generated using the Aurora S-01 System, Automatic Chemiluminescence Immunoassay Analyzer.
- Assay results obtained in individual laboratories may vary from data presented.

Limit of Blank (LoB) and Limit of Detection (LoD)

- The Limit of Blank and The Limit of Detection were determined in accordance with the CLSI (Clinica I and Laboratory Standards Institute) EP17-A requirements.
- The Limit of Blank is the 95th percentile value from $n \ge 20$ measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.
- The observed LoB value was ≤ 10 pg/mL.
- The observed LoD value was ≤ 15 pg/mL.

Accuracy

Intra Assay Variation

• Within run variation was determined by replicate determination (n=10) of three different control sera in one assay. The within assay variability is ≤10.0%.

Inter Assay Variation

• Between run variation was determined by replicate measurements (n=10) of three different control sera in 3 different lots. The between assay variability is ≤15.0%.

Intra-Assay, n=10	Inter-Assay, n=10×3
-------------------	---------------------

Intra-Assay, n=10			Inter-Assay, n=10×3		
Sample	Mean (pg/mL)	CV	Sample	Mean (pg/mL)	CV
1	39.830	3.56 %	1	38.337	5.41 %
2	197.040	4.54 %	2	210.163	5.87 %

Linearity

- The linearity was determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP6-A requirements.
- The linearity range was verified by more than 6 concentration levels which encompass or be equal to the minimum and the maximum values of linearity range and duplicate assays (n=3) at all levels
- The Estradiol assay kit has been demonstrated to be linear from 15 pg/mL to 1000 pg/mL, regression ≥0.99 and max diff ≤ 15% in this interval.

Specificity

Cross-Reactivity

- A study was performed based on guidance from CLSI EP7-A2.
- The cross-reactants listed below were evaluated to determine whether E2 concentrations were affected when using the Estradiol assay.

	<u> </u>	,
Cross-Reactant	Cross-Reactant	% Cross-Reactant
Cross-Reactant	Concentration	Bias
E1	5 ng/mL	≤ 10%
E3	50 ng/mL	≤ 10%
Norgestrel	50 ng/mL	≤ 10%

Interference

- A study was performed based on guidance from CLSI EP7-A2.
- Potentially interfering substances were evaluated to determine whether E2 concentrations were affected when using the Estradiol assay. Samples containing the potential interferents were prepared at two E2 concentrations. The samples were assayed, and the E2 concentrations of the spiked samples were compared to the reference samples.


Potential Interferent	Interferent	% Interferent Bias
	Concentration	

Potential Interferent	Interferent Concentration	% Interferent Bias
Bilirubin	20 mg/dL	≤ 10%
НЬ	500 mg/dL	≤ 10%
Intralipid	1000 mg/dL	≤ 10%
Total protein	10 g/dL	≤ 10%
RF	1000IU/mL	≤ 10%
ANA	400AU/mL	≤ 10%
НАМА	600ng/mL	≤ 10%


Reference

- 1. Wilke TJ, Utley DJ. Total Testosterone, Free Androgen Index, Calculated Free Testosterone, and Free Testosterone by Analog RIA Compared in Hirsute Women and in Otherwise-Normal Women with Altered Binding of Sex-Hormone-Binding Globulin. Clin Chem. 33:1373-1375; 1987.
- 2. GPNotebook-reference range (oestradiol) Retrieved on 27 September 2009.
- 3. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration[J]. Climacteric. 2005,8 (1 Suppl 1): 3-63.
- 4. Ryan KJ. Biochemistry of aromatase: significance to female reproductive physiology. Cancer Res. 1982 Aug;42(8 Suppl):3342s-3344s.
- 5. Naunton M, Al Hadithy AF, Brouwers JR, Archer DF. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause. 2006 May-Jun;13(3):517-27.
- Estradiol blood test: MedlinePlus Medical Encyclopedia. medlineplus.gov. Retrieved 6 May 2019.
- 7. Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P, Stricker R. Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin Chem Lab Med. 2006;44(7):883-7.


Symbols













EC REP

IVD	In Vitro diagnostic medical device

EU Representative

REF Catalogue Numb	oer
--------------------	-----


REAGENT Reager	nt
----------------	----

R1	Microparticles
ILTI	Microparticles

Conjugate

Contact Information

Medunion S.L.
Carrer de Tapioles 33, 2-1, 08004,
Barcelona, SPAIN.



24-hour service hotline: +968-97058350
After-sale Service Center: Carbon Technologies LLC

C E

Release Date: Date of Manufacture: